Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Filippo deBraud"'
Autor:
Federico Nichetti, Marco Silvestri, Luca Agnelli, Andrea Franza, Chiara Pircher, Simone Rota, Paolo Ambrosini, Giuseppe Fotia, Jennifer Hüllein, Giovanni Randon, Panna Lajer, Federica Perrone, Elena Tamborini, Giuseppe Leoncini, Jorgelina Coppa, Michele Droz Dit Busset, Sara Pusceddu, Massimo Milione, Federica Morano, Filippo Pietrantonio, Giancarlo Pruneri, Vincenzo Mazzaferro, Daniel B. Lipka, Bruno Christian Köhler, Daniel Hübschmann, Stefan Fröhling, Filippo deBraud, Monica Niger
Publikováno v:
Cancer Medicine, Vol 13, Iss 23, Pp n/a-n/a (2024)
ABSTRACT Background The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6‐methylguanine‐DNA methyltransferase (MGMT) silencing may occur in a subset of PAC tumors, w
Externí odkaz:
https://doaj.org/article/3eb55c237a314b16a53fe6575369b7af
Autor:
Monica Niger, Federico Nichetti, Andrea Casadei‐Gardini, Federica Morano, Chiara Pircher, Elena Tamborini, Federica Perrone, Matteo Canale, Daniel B. Lipka, Andrea Vingiani, Luca Agnelli, Anna Dobberkau, Jennifer Hüllein, Felix Korell, Christoph E. Heilig, Sara Pusceddu, Francesca Corti, Michele Droz, Paola Ulivi, Michele Prisciandaro, Maria Antista, Marta Bini, Laura Cattaneo, Massimo Milione, Hanno Glimm, Bruno C. Köhler, Giancarlo Pruneri, Daniel Hübschmann, Stefan Fröhling, Vincenzo Mazzaferro, Filippo Pietrantonio, Maria Di Bartolomeo, Filippo deBraud
Publikováno v:
Molecular Oncology, Vol 16, Iss 14, Pp 2733-2746 (2022)
Biliary tract cancers (BTCs) have poor prognosis and limited therapeutic options. The impact of O6‐methylguanine‐DNA methyltransferase (MGMT) inactivation in advanced BTC patients is not established. We investigated the prevalence, prognostic, an
Externí odkaz:
https://doaj.org/article/3b4516fdda224755a9583e4ef6af9f00
Autor:
Massimo Milione, Rosalba Miceli, Francesco Barretta, Alessio Pellegrinelli, Paola Spaggiari, Giovanna Tagliabue, Giovanni Centonze, Cinzia Paolino, Alessandro Mangogna, Ketevani Kankava, Sara Pusceddu, Luca Giacomelli, Ambra Corti, Christian Cotsoglou, Vincenzo Mazzaferro, Gabriella Sozzi, Filippo deBraud, Giancarlo Pruneri, Andrea Anichini
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 5, Iss 4, Pp 217-226 (2019)
Abstract Microenvironment‐related immune and inflammatory markers, when combined with established Ki‐67 and morphology parameters, can improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms (GEP‐NENs). Therefore,
Externí odkaz:
https://doaj.org/article/9b2429aeffb84a6f86fea61aaea869fe
Autor:
Darawan Rinchai, Elena Verzoni, Veronica Huber, Agata Cova, Paola Squarcina, Loris De Cecco, Filippo deBraud, Raffaele Ratta, Matteo Dugo, Luca Lalli, Viviana Vallacchi, Monica Rodolfo, Jessica Roelands, Chiara Castelli, Damien Chaussabel, Giuseppe Procopio, Davide Bedognetti, Licia Rivoltini
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 6, Pp n/a-n/a (2021)
Abstract Background The combination of immune checkpoint blockade (ICB) with standard therapies is becoming a common approach for overcoming resistance to cancer immunotherapy in most human malignancies including metastatic renal cell carcinoma (mRCC
Externí odkaz:
https://doaj.org/article/d78d15107286485db70ae3a5cc239824
Autor:
Giuseppe Procopio, Elena Verzoni, Isabella Testa, Nicola Nicolai, Roberto Salvioni, Filippo DeBraud
Publikováno v:
Therapeutic Advances in Urology, Vol 4 (2012)
The molecular-targeted agent sorafenib is the first anticancer agent able to slow the progression of advanced/metastatic renal cell carcinoma, a tumor that was formerly refractory to conventional therapy. Experience from everyday clinical practice an
Externí odkaz:
https://doaj.org/article/7aa8e51f91e441bc860506c623bc8089
Autor:
Mario P. Colombo, Stefano Manfredi, Gustavo Galmozzi, Alfonso Marchianò, Gabriele Papagni, Marco Votta, Roberto Salvioni, Giovanni Apolone, Michele Torresani, Oliviero Rinaldi, Franco Valenza, Maria Grazia Daidone, Andrea Frignani, Filippo DeBraud, Pierangelo Spada, Giancarlo Pruneri, Vito Ladisa
Publikováno v:
Tumori Journal. 106:193-202
Background: The rapid spread of coronavirus disease (COVID-19) is affecting many countries. While healthcare systems need to cope with the need to treat a large number of people with different degrees of respiratory failure, actions to preserve aliqu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b102a36ada2411ed6ffc1cfa67943398
https://doi.org/10.1177/0300891620923790
https://doi.org/10.1177/0300891620923790
Autor:
Elena, Verzoni, Sara, Pusceddu, Roberto, Buzzoni, Enrico, Garanzini, Angela, Damato, Pamela, Biondani, Isabella, Testa, Paolo, Grassi, Emilio, Bajetta, Filippo, de Braud, Filippo, DeBraud, Giuseppe, Procopio
Publikováno v:
Future Oncology. 10:1611-1617
ABSTRACT: Aim: Only few efforts have been taken to investigate the potential existence of disease-specific differences in the safety profile of everolimus. We analyze here the correlation between different patient and tumor characteristics on the saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13d53345847ab14e04833a1b7132bf5
https://doi.org/10.2217/fon.14.31
https://doi.org/10.2217/fon.14.31
Autor:
Roberto Buzzoni, Davide Citterio, Vincenzo Mazzaferro, Filippo DeBraud, Massimo Milione, Marco Bongini, Antonio Facciorusso, Sara Pusceddu, Jorgelina Coppa
Publikováno v:
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 43(2)
Functional well-differentiated neuroendocrine tumours (NET) with liver metastases represent a therapeutic challenge with few alternative options in guidelines. In these patients, the role of surgical resection of the primary tumour is controversial.F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::354cf557a5239a743a609ac5341d05fa
https://pubmed.ncbi.nlm.nih.gov/27956320
https://pubmed.ncbi.nlm.nih.gov/27956320
Autor:
Roberto Salvioni, Nicola Nicolai, Giuseppe Procopio, Isabella Testa, Filippo DeBraud, Elena Verzoni
Publikováno v:
Therapeutic Advances in Urology, Vol 4 (2012)
The molecular-targeted agent sorafenib is the first anticancer agent able to slow the progression of advanced/metastatic renal cell carcinoma, a tumor that was formerly refractory to conventional therapy. Experience from everyday clinical practice an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cf09979f8a1b47b609154f86af10888
https://doi.org/10.1177/1756287212457216
https://doi.org/10.1177/1756287212457216
Autor:
Chiara Mazzetta, Roberto Orecchia, Anna Morra, Gianpiero Catalano, Barbara Alicja Jereczek-Fossa, Fausto Chiesa, Daniela Alterio, L.C. Bianchi, Roberto Bruschini, A. Rocca, Filippo DeBraud, Marcella Pasetti
Publikováno v:
Strahlentherapie und Onkologie. 180:425-433
Despite numerous randomized trials suggesting a benefit of unconventional fractionation in locally advanced head and neck cancer, the role of this approach in nasopharyngeal carcinoma is debatable. Based on the current clinical experience, the author
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e70b384df35e6882245c949a5cb6e80
https://doi.org/10.1007/s00066-004-1202-9
https://doi.org/10.1007/s00066-004-1202-9